Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lechner

Showing results (171-180 of 175) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 175 results.
Journal of Medicinal Chemistry|October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's diseaseXiaohu Zhang, John E Tellew, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|January 15, 2009
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacyMarion C Lanier, Manisha Moorjani, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationshipsDeborah H Slee, Manisha Moorjani, Xiaohu Zhang, et al.
Rhinology|July 28, 2022
The COVANOS trial - insight into post-COVID olfactory dysfunction and the role of smell trainingM Lechner, J Liu, N Counsell, et al.
Rhinology|July 16, 2023
Position paper on olfactory dysfunction: 2023K L Whitcroft, A Altundag, P Balungwe, et al.
Pageof 18

Showing results (171-180 of 175) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 175 results.
Journal of Medicinal Chemistry|October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's diseaseXiaohu Zhang, John E Tellew, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|January 15, 2009
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacyMarion C Lanier, Manisha Moorjani, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationshipsDeborah H Slee, Manisha Moorjani, Xiaohu Zhang, et al.
Rhinology|July 28, 2022
The COVANOS trial - insight into post-COVID olfactory dysfunction and the role of smell trainingM Lechner, J Liu, N Counsell, et al.
Rhinology|July 16, 2023
Position paper on olfactory dysfunction: 2023K L Whitcroft, A Altundag, P Balungwe, et al.
Pageof 18